Opticin was extracted from normal and OA human cartilage using guanidinium chloride (4 M) extraction and examined by Western blotting. Human MMP 1, -2, -3, -7, -8, -9 and ADAMTS-4, -5 proteolytic activities on opticin were analyzed on normal and OA cartilage extracts incubated for 0−24 hours Results: One of the emerging observations was that all MMPs and ADAMTS tested, except MMP-9, cleaved opticin in both normal and OA specimens. Interestingly, MMP-7 and -8 were the most effective, and degradation occurred as early as 15 minutes of incubation. At which time, degradation was almost complete for MMP-7, suggesting that this molecule is a preferential substrate for this enzyme. In contrast, MMP-1 was the least effective and degradation was noted after an incubation of 16 hours. The others enzymes showed degradation starting at about 2 hours. The degradation pattern, except for MMP-7 in which degradation appeared independent of the specimen types, was different between normal and OA. In general, the degradation pattern was slower in normal than in OA specimens, reflecting an increased sensitivity of opticin to degradation when the cartilage was damaged. Fragments were also detected, but the number and size differed depending on the protease. This indicates different digestion sites among the proteases. Surprisingly, MMP-1 and -2 generated different opticin degradation fragments when normal were compared to OA specimens. The different opticin protease cleavage sites are currently under study.
Purpose: Diabetes mellitus is an important risk factor for osteoarthritis (OA), but the mechanisms involved are largely unknown. In chondrocytes, glucose is essential for energy production and the synthesis of matrix components. Diabetic patients can experience extended episodes of hyper-and hypoglycemia that are likely to affect the delivery of glucose to the synovial joint and its availability to chondrocytes. Glucose transport is the limiting step in glucose utilization and the facilitative glucose transporter-1 (GLUT-1) is the major glucose transporter in chondrocytes. This study aimed at comparing the ability of normal and OA chondrocytes to regulate glucose uptake and GLUT-1 levels in response to high and low extracellular glucose concentrations. Methods: Normal human chondrocytes were isolated from the femoral condyles of multi-organ donors. OA chondrocytes were isolated from the cartilage obtained from patients undergoing total knee replacement surgery. Serum-starved subconfluent chondrocyte cultures were incubated in media with 0, 10 or 30 mM glucose. Total GLUT-1 content was evaluated by western blotting. Glucose transport was determined by measuring the uptake of non-metabolizable 2-Deoxy-D-2-[2,6-3 H] glucose into chondrocytes for 30 minutes at 37ºC. GLUT-1 gene expression was measured by Real Time PCR. To determine the role of lysosomes in GLUT-1 regulation, chondrocyte cultures in regular (10 mM glucose) or high glucose (30 mM) medium were treated with 20 mM chloroquine, an inhibitor of lysosome function, for the last 6 hours of an 18 hour incubation period. Results: Treatment of normal chondrocytes with 30 mM glucose for either 18 or 48 hours significantly decreased 2-Deoxy-D-Glucose uptake (75.4±3.6% and 71.5±2.6%, respectively) and GLUT-1 protein levels (68.2±9.1% and 64.6±6.0%, respectively) relative to cells cultured under 10 mM glucose. In contrast, 2-Deoxy-D-Glucose uptake (102.5±3.1%) and GLUT-1 levels (116.51±9.6%) remained unchanged in OA chondrocytes cultured for 48 hours in the high glucose medium. GLUT-1 mRNA levels, either in normal or OA chondrocytes, were not affected by treatment with high glucose for 6, 12 or 24 h. Similarly to normal cells, OA chondrocytes responded to glucose deprivation by increasing 2-Deoxy-D-Glucose uptake (128±2%) and total GLUT-1 levels (137.8±8.6%). Treatment with 20 mM chloroquine significantly increased total GLUT-1 protein in normal chondrocytes, both under regular (10 mM) and high glucose conditions. Conclusions: OA chondrocytes are capable of upregulating the net rate of glucose transport and GLUT-1 protein when deprived of glucose, suggesting that they are capable of sensing and adjusting to low extracellular glucose concentrations. However, unlike normal chondrocytes, OA chondrocytes fail to downregulate glucose transport and GLUT-1 protein under high glucose concentrations. This may lead to an abnormally high intracellular glucose concentration, which in turn may lead to altered cell function and the formation of glycation end products during extended periods of hyperglycemia in vivo. The lack of significant differences in GLUT-1 mRNA, together with GLUT-1 accumulation in normal chondrocytes exposed to chloroquine, indicate that GLUT-1 downregulation depends on lysosomal degradation. The role of lysosomal function in the inability of OA chondrocytes to adequately respond to high glucose remains to be elucidated. Purpose: Previously we have shown that cartilage chondrocyte alkaline phosphatase (ALP) is up regulated in active osteoarthritis (OA) and down regulated in calcium pyrophosphate dihydrate (CPPD) crystal deposition disease. Furthermore, CPPD crystals can be dissolved by the action of ALP provided that the enzyme is bound to the crystals. Modulating the action of ALP would then suggest a possible route to affect these conditions. To obtain a better understanding of the action of ALP on CPPD crystal dissolution, we investigated inhibition by endogenous amino acids on ALP substrates; organic phosphate, inorganic pyrophosphate, and CPPD crystals. Methods: CPPD crystals were made using established methods developed in our laboratory. The phosphatase (Piase), pyrophosphate hydrolase (PPiase), and CPPD crystal dissolution activities of tissue nonspecific alkaline phosphatase (TNAP) were investigated in vitro using cysteine and mercaptopyruvate (MPA) as inhibitors of Bovine kidney ALP. Enzyme activity was determined by measuring liberated inorganic phosphate (Pi) from p-Nitrophenyl phosphate (pNPP), or Sodium pyrophosphate, at specific times and conditions. CPPD crystal dissolution was assessed by measuring [Pi] liberated into solution in the presence of TNAP. To assess enzyme inhibition, kinetics parameters such as Vmax and Km, were determined and specific activities were calculated from Initial Velocity, Eadie-Hofstee, Simple, Dixon, and Secondary plots. Assays were run under physiologic conditions with Tris-HCl buffer, pH = 7.4 and at 37ºC. TNAP was at 200U/L and the buffer was supplemented with 1 mM Ca ++ and 1 mM Mg ++ . Enzyme activity was expressed as nmoles Pi/unit TNAP/minute. Results: At physiologic concentration, cysteine had no inhibitory effect on any activity of TNAP. At 10× physiologic concentration, cysteine significantly inhibited phosphatase and pyrophosphate hydrolase activity but did not inhibit CPPD crystal dissolution. MPA and cysteine together inhibited TNAP's phosphatase and pyrophosphate hydrolase activity at physiologic concentration while CPPD crystal dissolution was only slightly inhibited. When the two inhibitors were increased to 10x physiologic concentration, all enzyme activity decreased significantly as is shown in the summary Purpose: Among the matrix metalloproteinases (MMPs), MMP-13 plays a major role in osteoarthritis (OA) due to its-rate limiting role in the collagen degradation. MMP-13 expression is regulated by a variety of transcription factors, including members of the ETS family such as ETS-2 and Elk-1, but the precise transcriptional mechanism is not completely understood. ESE-1 is expressed in non-epithelial tissues after treatment with inflammatory cytokines and we reported recently that ESE-1 represses the type II collagen gene (COL2A1) in human chondrocytes. These observations suggest a fundamental role of ESE-1 in cartilage degeneration and suppression of repair. The aim of this study was to determine whether ESE-1 participates in the MMP-13 transcriptional regulation in chondrocytes.
Methods:
The binding of in vitro-translated ESE-1 to the MMP-13 promoter was analyzed by electrophoretic mobility shift assay (EMSA) and supershift analysis. For knockdown of ESE-1 expression, the human chondrocytic C-28/I2 cells were transfected with a pool of four individual siRNA oligonucleotides against ESE-1 or control nonspecific siRNA. After incubation for 72 hours, the knockdown was confirmed by real time PCR and Western blotting, and MMP-13 mRNA was analyzed by real time PCR. MMP-13 protein in Ese1 (Elf3)-deficient mice was addressed by immunohistochemical staining. Results: Three highly conserved ETS binding sites were revealed in the proximal region of the MMP-13 promoter. By EMSA and supershift analysis, we detected specific binding of ESE-1 to all three sites in the proximal MMP-13 promoter, with stronger binding to the site containing 2 tandem ETS sites. These results suggested that ESE-1 could be regulating the MMP-13 promoter activity. By using specific siRNA oligos, we knocked down the ESE-1 expression in C28/I2 cells. Real time PCR analysis revealed lower MMP-13 basal expression associated with ESE-1 knockdown. This result suggests that ESE-1 is necessary for maintaining the MMP-13 basal expression levels. Finally, the immunohistochemical analysis of the Elf3-deficient mouse cartilage revealed low or undetectable MMP-13 protein levels in comparison with age-matched wild type cartilage samples, although type II collagen staining was similar with no evidence of proteoglycan loss. Conclusions: Our previous results highlighted ESE-1 as an important transcriptional regulator of cartilage degenerative processes. After induction, ESE-1 transactivates both NOS2 and COX2 promoters by interacting with NFúB. In addition, we showed recently that ESE-1 represses the COL2A1 in human chondrocytes and that ESE-1 immunostaining is high in human OA cartilage, whereas it is not present or undetectable in control cartilage. In this work we show that ESE-1 binds directly to the MMP-13 proximal promoter region and that knocking down the ESE-1 expression leads to decreased MMP-13 basal expression levels. These results suggest that, among others, ESE-1 is a key factor for maintaining the MMP-13 basal expression. Moreover, our finding that MMP-13 protein levels are decreased or absent in the cartilage of Elf3-deficient mice further reinforces the role of the ESE-1 in maintaining MMP-13 basal expression. However, the lack of evidence of collagen degradation in wild type samples indicates that activation of the proenzyme requires additional stimuli. Altogether, our results suggest a fundamental role for ESE-1 in controlling MMP-13 gene expression in chondrocytes. Further work will be required to determine its role in progressive cartilage loss during OA. (mm), the bone mineralization patterns remain to be elucidated. To develop a better understanding of subchondral bone mineralization in osteoarthritis and to explore the utility of high voltage, high resolution x-ray microscopy in resolving bone structure, we studied the articular bone plate and subchondral bone trabeculae in ten cases of osteoarthritis using CPPD crystal deposition disease and osteoporosis cases as control tissues. Methods: Five mm coronal blocks were taken from the femoral condyles at cross sections where osteoarthritis was maximal and where articular cartilage was still present. These blocks were adjacent to blocks taken for routine diagnostic analysis. The formalin-fixed blocks were studied using a Comet Feinfocus 160.25 x-ray microscopy system (focal spot <1 mm). For this study, magnification was set at the highest practical level to obtain clear images, projection magnification = 28×. X-ray exposures were optimized to characterize the bone mineral structure (80 kV, 45 uA). Magnification was calibrated using a copper electron microscope grid diameter = 3 mm, with grid line width = 35 mm. Results: Samples clearly showed resolution of features less than 10 mm in width and demonstrated different mineralization density within bone structures. Figure 1 shows a sample range of the initial morphologic observations. The osteoporosis control, Fig. 1 .3 shows subchondral bone with similar density to that of the bone trabeculae (bars) as well as extensive but focal, trabecular microfractures with increased mineralization (arrow). Samples from osteoarthritis patients, Fig. 1 .2 and 1.3, demonstrated increased bone mineral density within the subchondral plate. However, Fig. 1 .3 showed extensive trabecular microfractures with highly mineralized density compared to normal trabeculae whereas Fig. 1 .2 did not. In Fig. 1 .4 from the calcium pyrophosphate crystal deposition disease, the image shows a morphologic pattern more closely resembling osteoporosis Fig. 1 .3 than osteoarthritis.
Conclusions: These studies show that X-ray microscopy is a promising tool to delineate subsets of subchondral bone response in osteoarthritis.
The observations confirm that subchondral osteosclerosis in osteoarthritis is related to increased bone mineral density of the subchondral bone plate irrespective of bone thickness. However, trabecular microfractures with increased mineralization density occurs only in a portion of patients with osteoarthritis. This indicates that the subchondral bone trabecular structure and mineralization distribution in osteoarthritis is heterogeneous. Most likely, this reflects different types of osteoarthritis with differential bone mineralization response, rather than different stages of the disease. 
